The goal of this program is to assist practicing physicians that care for patients with respiratory distress due to asthma symptoms via targeted education. This program will ensure that physicians are equipped with the knowledge to make informed, proactive management decisions that reduce exacerbation occurrences and hospitalizations, improve adherence rates, and improve quality of life for all patients with moderate-to-severe asthma.

RELEASED DATE: September 30, 2024
EXPIRATION DATE: September 30, 2025

This enduring educational program is designed to assist healthcare providers who care for adult patients with moderate-to-severe asthma in reducing exacerbations and hospitalizations and improving patient treatment adherence and quality of life. This program will help learners to better align treatment regimens with evidence-based asthma management guidelines, summarize evidence-based best practices to optimize patient education, and employ current clinical evidence on the use of biologic agents in patients with moderate-to-severe asthma.

RELEASED DATE: October 29, 2024
EXPIRATION DATE: October 29, 2025

This enduring activity is designed to help healthcare professionals focus on type 2 inflammatory pathways that can serve as potential therapeutic targets in patients with COPD. This program will also analyze current clinical trial safety and efficacy data on new and emerging biologics targeting mediators of type 2 inflammation for the treatment of COPD patients in a real-world setting.

RELEASED DATE: October 18, 2024
EXPIRATION DATE: October 18, 2025

This innovative educational series will be designed to meet the targeted needs of US-based pulmonologists involved in the diagnosis and management of US Veterans with COPD. Our program aims to enhance clinicians’ ability to review novel COPD diagnostic techniques and apply them into clinical practice for US Veterans; explore the value of the interleukin (IL)-4/13 and IL-33 signaling pathways in novel COPD treatments; and finally, assess current data on new and emerging therapies for the treatment of COPD. The enduring component of this program is designed to further extend its audience reach.

RELEASED DATE: March 01, 2024
EXPIRATION DATE: March 01, 2025

This program has been developed to educate practitioners who care for patients with chronic obstructive pulmonary disease (COPD) on the emerging role of pro-inflammatory cytokines in COPD progression and treatment, improve their understanding of the evolving clinician trial landscape, and impart strategies to improve patient education and communication. The program provides a unique opportunity to hear the patient’s perspective on their disease journey, and from the treating physician on the clinical strategy that was implemented to manage disease symptoms.

RELEASED DATE: October 30, 2024
EXPIRATION DATE: October 30, 2025

This program is designed to enhance clinicians’ ability to explain the roles of interleukins (IL)-4/13, IL-33 and other pro-inflammatory cytokine signaling pathways in the etiopathogenesis of chronic obstructive pulmonary disease (COPD) and its disease mechanism, discuss data from clinical studies investigating the clinical profiles of emerging therapies for the treatment of COPD, and describe multidisciplinary, shared decision-making strategies to improve patient-specific communication and education throughout each step of the care continuum of COPD.

RELEASED DATE: February 20, 2024
EXPIRATION DATE: February 20, 2025

This enduring will focus on improving the management of veterans who are suffering from moderate-to-severe asthma. The content will review strategies to provide care for veterans that aligns with evidence-based guidelines; review multidisciplinary treatment programs and build awareness of asthma management specific to veterans; and examine clinical trial data on agents approved for the treatment of moderate-to-severe asthma.

RELEASED DATE: August 30, 2024
EXPIRATION DATE: August 30, 2025

This enduring program consists of presentations from expert faculty and simulation challenge animations that will explain immune dysfunction and the pathogenesis of moderate-to-severe asthma, currently available and emerging targeted therapies used for asthma, and the usefulness and application of guidelines and biomarkers to guide treatment selection for this disease.

This enduring HoloVision™ activity is an online program designed to advance the abilities of US-based pulmonologists and respiratory therapists and provide the tools to determine an accurate diagnosis of COPD using new diagnostic methods; understand how interleukin (IL)-4/13 and IL-33 signaling pathways affect the pathophysiology of COPD; and review data from clinical studies of the clinical profiles of new and emerging treatments for COPD.

RELEASED DATE: March 01, 2024
EXPIRATION DATE: March 01, 2025

This program will focus on recognizing the clinical presentation, symptomatic burden, and patient risk factors associated with Chronic Rhinosinusitis With Nasal Polyps (CRSwNP), to improve its timely and accurate diagnosis in the VA setting. In addition, this activity will review the pathology of type 2 inflammation-mediated disease and its mechanism of action. Evidence-based treatment guidelines for the use of biologics will also be evaluated. In addition, this program will highlight the importance of employing a multidisciplinary team to develop optimal patient treatment plans.

RELEASED DATE: September 26, 2024
EXPIRATION DATE: September 26, 2025